drugset / Trial / NCT03558412
A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To explore the safety, tolerability, and clinical effects of decitabine combined with Second-line chemotherapy regimens for patients with relapsed or refractory T-lymphoblastic lymphoma.
Timeline
- Start
- 2018-06-01
- Primary completion
- 2019-12-01
- Completion
- 2020-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 10 mg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Cytarabine | Small molecule | — | Intravenous |
| Background | Epirubicin | Small molecule | — | Intravenous |
| Background | Etoposide | Small molecule | — | Intravenous |
| Background | Ifosfamide | Small molecule | — | Intravenous |
| Background | Methotrexate | Small molecule | — | Intravenous |
| Background | Vincristine | Small molecule | — | Intravenous |